Neurosense Therapeutics Ltd. (NRSN) Financial Statements

208 Followers

Neurosense Therapeutics Ltd. Financial Overview

Neurosense Therapeutics Ltd.'s market cap is currently $29.02M. The company's EPS TTM is $-0.22; its P/E ratio is -1.76; Neurosense Therapeutics Ltd. is scheduled to report earnings on March 31, 2026, and the estimated EPS forecast is $-0.20. See an overview of income statement, balance sheet, and cash flow financials.

	Mar 26	Mar 25	Mar 24	Dec 22	Dec 21
Income Statement
Total Revenue	$ 0.00	$ 0.00	$ 0.00	$ 0.00	$ 0.00
Gross Profit	$ 0.00	$ 0.00	$ 0.00	$ -89.00K	$ -3.00K
Operating Income	$ -11.09M	$ -9.90M	$ -12.05M	$ -13.55M	$ -5.59M
EBITDA	$ -11.07M	$ -9.88M	$ -9.64M	$ -12.23M	$ -2.88M
Net Income	$ -11.13M	$ -10.21M	$ -10.11M	$ -12.34M	$ -4.04M
Balance Sheet
Cash & Short-Term Investments	$ 166.00K	$ 3.38M	$ 2.64M	$ 7.09M	$ 11.06M
Total Assets	$ 1.03M	$ 4.58M	$ 3.19M	$ 7.71M	$ 11.43M
Total Debt	$ 170.00K	$ 73.00K	$ 142.00K	$ 211.00K	$ 1.83M
Net Debt	$ 4.00K	$ -3.31M	$ -2.50M	$ -3.33M	$ -9.23M
Total Liabilities	$ 2.59M	$ 1.99M	$ 4.94M	$ 2.09M	$ 2.42M
Stockholders' Equity	$ -1.56M	$ 2.58M	$ -1.76M	$ 5.62M	$ 9.01M
Cash Flow
Free Cash Flow	$ -7.68M	$ -10.14M	$ -8.38M	$ -7.66M	$ -1.56M
Operating Cash Flow	$ -7.67M	$ -10.13M	$ -8.35M	$ -7.59M	$ -1.54M
Investing Cash Flow	$ -8.00K	$ 1.00K	$ 3.47M	$ -3.54M	$ -17.00K
Financing Cash Flow	$ 4.43M	$ 10.91M	$ 3.98M	$ 3.69M	$ 11.90M

Currency in USD

Neurosense Therapeutics Ltd. Earnings and Revenue History

Income Statement >

Neurosense Therapeutics Ltd. Debt to Assets

Balance Sheet >

Neurosense Therapeutics Ltd. Cash Flow

Cash Flow >

Neurosense Therapeutics Ltd. Forecast EPS vs Actual EPS

Earnings >